A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

Key Inclusion Criteria: * The participant has a diagnosis of migraine as defined by International Classification of Headache Disorders Third Edition (ICHD-3) guidelines confirmed at the Screening Visit. * The participant has a history of migraine onset ≥ 12 months prior to the Screening Visit. * The participant has a migraine onset at ≤50 years of age. * The participant has ≥4 migraine days per month for each month within the past 3 months prior to the Screening Visit. * The participant has documented evidence of treatment failure in the past 10 years of at least 1 to 4 (maximum) different migraine preventive medications. Key Exclusion Criteria: * The participant has previously been dosed with an anti-pituitary adenylate cyclase-activating peptide (anti-PACAP treatment). * The participant has confounding and clinically significant pain syndromes. * The participant has a diagnosis of acute or active temporomandibular disorder. * The participant has a history or diagnosis of confounding headaches. Additional protocol-defined criteria apply.